IP Library Granted Patent US 10,981,942
Granted Patent B2
US 10,981,942 · App. 16/694,642 · Granted Apr 20, 2021

Crystalline form of benzylbenzene SGLT2 inhibitor

Inventors: Mengzhuang Cai (Shanghai, CN); Qian Liu (Shanghai, CN); Ge Xu (Shanghai, CN); Binhua Lv (Shanghai, CN); Brian Seed (Boston, MA); Jacques Roberge (Princeton, NJ)
Assignee: THERACOS SUB, LLC
C07H1/06A61K31/351A61P3/10C07D309/10C07H7/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,981,942
App. No.
16/694,642
Granted
Apr 20, 2021
Kind
B2
Abstract

Provided are crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2. The invention also provides pharmaceutical compositions, methods of preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition.

Claims (11)

1. A crystalline form of the compound of the formula:

characterized by a Raman spectra that comprises three or more peaks at about 353, 688, 825, 1178, 1205, 1212, 1608, 2945, 3010 and 3063 cm −1 .

2. The crystalline form in accordance with claim 1 , characterized by a Raman spectra that comprises peaks at about 353, 688, and 825 cm −1 .

3. The crystalline form in accordance with claim 1 , characterized by a Raman spectra that comprises peaks at about 1178, 1205, and 1212 cm −1 .

4. The crystalline form in accordance with claim 1 , characterized by a Raman spectra that comprises peaks at about 1608, 2945, 3010 and 3063 cm −1 .

5. The crystalline form in accordance with claim 1 , characterized by a Raman spectra that comprises peaks at about 353, 688, 825, 1608, 2945, 3010 and 3063 cm −1 .

6. The crystalline form in accordance with claim 1 , characterized by a Raman spectra that comprises peaks at about 1178, 1205, 1212, 1608, 2945, 3010 and 3063 cm −1 .

7. The crystalline form in accordance with claim 1 , characterized by a Raman spectra that comprises peaks at about 353, 688, 825, 1178, 1205, and 1212 cm −1 .

8. The crystalline form in accordance with claim 1 , characterized by the Raman peaks substantially in accordance with those of FIG. 4 .

9. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a crystalline form of the compound of claim 1 .

10. The crystalline form in accordance with claim 1 , characterized by a Raman spectra that comprises peaks at about at about 353, 688, 825, 1178, 1205, 1212, 1608, 2945, 3010 and 3063 cm −1 .

Assignments (5)
CHANGE OF NAME Recorded Jan 10, 2023
From: THERACOS SUB, LLC
To: THERACOSBIO, LLC
Reel/Frame 062351/0605 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 12, 2020
From: CAI, MENGZHUANG
To: THERACOS, INC.
Reel/Frame 054623/0784 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 12, 2020
From: LIU, QIAN
To: THERACOS, INC.
Reel/Frame 054623/0793 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 12, 2020
From: XU, GE; LV, BINHUA; SEED, BRIAN; ROBERGE, JACQUES Y.
To: THERACOS, INC.
Reel/Frame 054623/0812 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 12, 2020
From: THERACOS, INC.
To: THERACOS SUB, LLC
Reel/Frame 054623/0819 →
Priority Claims (1)
WO PCT/CN2010/073865 · Jun 12, 2010 · international
Continuity (4)
Continuation 15804074 · Nov 6, 2017
Division 14627693 · Feb 20, 2015
Division 13158724 · Jun 13, 2011
Related Publication 20200239510A1 · Jul 30, 2020
Cited By (2)
US 12,274,689 US 12,594,243